T Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
By A. Facciabene, Gregory T. Motz, George Coukos. Cancer Research, 2012
765 citations recorded by the source corpus.
Regulatory T cells (Tregs) are found infiltrating tumors in a vast array of tumor types, and tumor-infiltrating Tregs are often associated with a poor clinical outcome. Tregs are potent immunosuppressive cells of the immune system that promote progression of cancer through their ability to limit antitumor immunity and promote angiogenesis. Here, we discuss the ways in which Tregs suppress the antitumor immune response, and elaborate on our recent discovery that Tregs make significant direct contributions to tumor angiogenesis. Further, we highlight several current therapies aimed at the elimination of Tregs within cancer patients. Given the multifaceted role of Tregs in cancer, a greater understanding of their functions will ultimately strengthen future therapies.
Subfields: Immunology
View Paper: https://www.semanticscholar.org/paper/042604d70aa61ef14379c5b045e7a18b22c10b60
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- George Coukos
- G. Freeman
- K. Kaluza
- Jaikumar Duraiswamy
- E. Wherry
- Lieping Chen
- Arlene H. Sharpe
- Rakesh K. Jain
Citations in the corpus
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T Cell Rejection Function in Tumors (2013, background): “CD4CD25Foxp3 T cells (Tregs) play critical roles in the control of anti-tumor immune responses (21-22, 30-38).”
- NF-κB, an Active Player in Human Cancers (2014, neutral): “Treg infiltration into the tumor not only leads to tumor immune escape, but also promotes angiogenesis through the release of various chemokines (TGF-β , IL-10, and IL-35) (18).”
- Deubiquitylating enzymes and drug discovery: emerging opportunities (2017, background): “As T reg cells restrict antitumour immune responses and promote tumour survival 133 , these results suggest that depletion of FOXP3 in T reg cells by targeting USP7 and USP21 offer promise for anticancer immunotherapies.”